IQVIA and Duke Clinical Research Institute Forge Strategic Partnership to Tackle Obesity
In a significant development for the clinical research landscape, IQVIA Holdings Inc. (NYSE: IQV) has announced a strategic collaboration with the Duke Clinical Research Institute (DCRI) aimed at advancing clinical research in obesity and related conditions. This partnership, revealed on February 10, 2026, promises to leverage the strengths of both organizations to enhance the efficacy and efficiency of clinical trials in this critical area of healthcare.
1. Uniting Forces for Enhanced Clinical Trials
The collaboration between IQVIA, a global leader in clinical research services, and DCRI, one of the largest academic clinical research organizations, is poised to set new standards in the conduct of clinical research. By streamlining operational frameworks—from governance to data flow and site-level execution—the partnership is designed to accelerate clinical trial processes and improve outcomes for sponsors, regulators, and most importantly, patients.
Dr. Jeffrey Spaeder, Chief Medical and Scientific Officer at IQVIA, stated, “By combining IQVIA’s operational excellence and global reach with DCRI’s academic rigor, we are setting a new standard for prospective collaboration between life science service companies and academic research organizations.” The aim is to maximize trial efficiency, shorten timelines, and ultimately deliver impactful therapies to patients more swiftly.
2. Extensive Experience in Obesity Trials
IQVIA brings a wealth of experience to this collaboration, having conducted over 120 obesity trials and enrolling more than 90,000 patients. The company has supported clinical development, including operations and patient support, for all FDA-approved GLP-1 therapies to date. This extensive background provides a robust foundation for sponsors exploring obesity and metabolic research, positioning the collaboration to drive meaningful improvements in patient care.
Dr. Adrian Hernandez, Executive Director of DCRI, emphasized the importance of their combined strengths, stating, “DCRI’s proven infrastructure for trial operations—along with our deep expertise in cardiometabolic and renal disease—enables us to design and execute trials that are both scientifically robust and operationally agile.”
3. Key Benefits of the Collaboration
The strategic partnership aims to deliver several key benefits:
- Expanded Access: The collaboration will enhance access to diverse patient populations across 56 countries and more than 3,000 sites, allowing for more representative and comprehensive trial results.
- Thought Leadership: The collaboration will extend the impact of thought leadership, facilitated by DCRI’s clinical and data science faculty’s involvement in presenting results, thus enhancing the visibility and applicability of findings.
- Leveraging Expertise: The partnership will capitalize on DCRI’s pioneering research in GLP-1 receptor agonists and SGLT2 inhibitors, combined with IQVIA’s advanced analytics and real-world data capabilities to optimize trial design and execution.
4. Looking Ahead
As the obesity epidemic continues to challenge public health, this collaboration between IQVIA and DCRI stands as a beacon of hope. By combining their respective strengths, the two organizations are well-positioned to significantly enhance the landscape of clinical research in obesity and related conditions, ultimately improving patient care and outcomes.
With the global healthcare community eagerly anticipating advancements in obesity treatment, this partnership marks a pivotal moment in the journey towards more effective therapies and better patient outcomes. As they embark on this ambitious endeavor, both IQVIA and DCRI reaffirm their commitment to fostering innovation and excellence in clinical research.
